Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview
The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period.
GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion)
Buy the Full Report to Know More about the GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Forecast
The Glucagon-Like Peptide-1 Receptor (GLP-1R) agonists in the type 2 diabetes and obesity market report covers 68 geographical markets and provides a forecast model for the market through 2033. This report contains sales forecast extrapolations for the 7 major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) and an additional 61 geographical markets (61M), totaling 68 markets (68M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare and POLI Price Intelligence databases.
| Market Size (2023) | $39.2 Billion |
| Key Countries | · Africa
· APAC · Europe · LATAM · Middle East · North America |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Segmentation by Regions
North America accounted for the highest GLP-1R Agonists in the Type 2 Diabetes and Obesity market share in 2023.
The key regions in the GLP-1R agonists in the type 2 diabetes and obesity market are Africa, APAC, Europe, LATAM, the Middle East, and North America. APAC and Europe also had a significant share of the GLP-1R agonists in the type 2 diabetes and obesity market.
GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Analysis by Regions, 2023 (%)
Buy the Full Report for More Country Insights into the GLP-1R Agonists in the Type 2 Diabetes and Obesity Market
Key 7MM Events Driving the 68M Forecast Extrapolation
A few of the key events occurring in the 7MM that drive the trajectory of the 68M forecast for GLP-1R agonists in the type 2 diabetes and obesity markets between 2023 and 2033 are Saxenda Patent Expiry, Victoza Patent Expiry, Suliqua Patent Expiry, and Victoza Patent Expiry among others.
GLP-1R Agonists in the Type 2 Diabetes and Obesity Regional Outlook (Value, $ Billion, 2023-2033)
- Africa
- APAC
- Europe
- LATAM
- Middle East
- North America
Scope
This publication is an expanded version of the Excel model containing the patient-based forecast sales for Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity, covered in GlobalData’s report “Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven -Market Drug Forecast and Market Analysis”, published in April 2024. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in the Type 2 Diabetes and Obesity therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Bayer
Roche
Novartis
AbbVie
RegenxBio
Outlook Therapeutics
Kodiak Sciences
Opthea
Apellis Pharmaceuticals
Iveric Bio
Genentech
Chugai
Bausch + Lomb
Clinigen
Cheplapharm
Ribomic
Unity Biotechnology
Clearside Biomedical
EyePoint Pharmaceuticals
Ocular Therapeutix
Ashvattha Therapeutics
Outlook Therapeutics
Adverum Biotechnlologies
Formycon
Essex Bio
Xbrane Biopharma
Celltrion
Lupin
Viatris
Amgen
Samsung Bioepis
Senju
SamChunDang Pharm Co Ltd
Table of Contents
Frequently asked questions
-
What was the GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M in 2023?
The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was valued at $39.2 billion in 2023.
-
Which region had the highest share in the 68M GLP-1R agonists in the type 2 diabetes and obesity market?
North America held the highest share in the GLP-1R agonists in the type 2 diabetes and obesity market across the 68M in 2023.
-
What are the key 7MM events driving the 68M forecast extrapolation?
A few of the key events occurring in the 7MM that drive the trajectory of the 68M forecast for GLP-1R agonists in the type 2 diabetes and obesity markets between 2023 and 2033 are Saxenda Patent Expiry, Victoza Patent Expiry, Suliqua Patent Expiry, and Victoza Patent Expiry among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports

